Department of Pulmonary and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH.
Department of Internal Medicine, University of Connecticut, CT.
Chest. 2020 Dec;158(6):2546-2555. doi: 10.1016/j.chest.2020.06.053. Epub 2020 Jul 3.
European Society of Cardiology (ESC) and European Respiratory Society (ERS) guidelines include thermodilution cardiac index (TDCI) and mixed venous oxygen saturation (SvO) as two of the three hemodynamic determinations used in risk assessment of patients with pulmonary arterial hypertension (PAH). SvO may be a better measurement than TDCI to assess prognosis in patients with either idiopathic or heritable PAH.
What is the concordance between TDCI and SvO ESC/ERS risk group allocation and their prognostic value in patients with PAH?
In this retrospective study, we assessed the correlation between SvO and TDCI in patients with idiopathic and heritable PAH. We determined concordance in the ESC/ERS risk group allocation and association with survival, both at baseline and follow-up.
A total of 158 patients (mean age, 58 ± 17 years; 72% women) with idiopathic (91%) and heritable (9%) PAH were included. There was moderate association between TDCI and SvO (r = 0.50; 95% CI, 0.37-0.62). Weighted kappa revealed a fair agreement between TDCI and SvO (κ = 0.30; 95% CI, 0.18-0.42), with concordance in risk group allocation in 49% of patients. During a median follow-up of 45 months (interquartile range, 23-105), 62 patients (39%) died. Using Kaplan-Meier analysis, survival was impacted by the SvO (log rank = 0.002) but not by the TDCI risk group allocation (log-rank = 0.51). Using the Cox proportional hazard model, adjusted for age and sex, SvO (but not TDCI) was associated with mortality (hazard ratio per 1% change, 0.94; 95% CI, 0.91-0.97; P < .001).
When using the cutoffs proposed by the ESC/ERS guidelines, we noted poor concordance in risk score allocation between TDCI and SvO. In patients with idiopathic or heritable PAH, SvO measurements are superior to TDCI in predicting long-term mortality.
欧洲心脏病学会(ESC)和欧洲呼吸学会(ERS)指南将热稀释心指数(TDCI)和混合静脉血氧饱和度(SvO)作为肺动脉高压(PAH)患者风险评估中使用的三个血流动力学测定值中的两个。在特发性或遗传性 PAH 患者中,SvO 可能是评估预后的更好指标,优于 TDCI。
TDCI 和 SvO 与 ESC/ERS 风险组分配的一致性及其在 PAH 患者中的预后价值如何?
在这项回顾性研究中,我们评估了特发性和遗传性 PAH 患者中 SvO 与 TDCI 的相关性。我们确定了 ESC/ERS 风险组分配的一致性,并确定了与基线和随访时生存的关联。
共纳入 158 例特发性(91%)和遗传性(9%)PAH 患者(平均年龄 58±17 岁,72%为女性)。TDCI 和 SvO 之间存在中度相关性(r=0.50;95%CI,0.37-0.62)。加权kappa 显示 TDCI 和 SvO 之间存在适度一致性(κ=0.30;95%CI,0.18-0.42),其中 49%的患者风险组分配一致。在中位随访 45 个月(四分位距,23-105)期间,62 例患者(39%)死亡。Kaplan-Meier 分析显示,SvO(对数秩检验=0.002)而非 TDCI 风险组分配(对数秩检验=0.51)影响生存。使用 Cox 比例风险模型,调整年龄和性别后,SvO(而非 TDCI)与死亡率相关(每 1%变化的危险比,0.94;95%CI,0.91-0.97;P<.001)。
当使用 ESC/ERS 指南提出的截断值时,我们注意到 TDCI 和 SvO 之间风险评分分配的一致性较差。在特发性或遗传性 PAH 患者中,SvO 测量值在预测长期死亡率方面优于 TDCI。